Literature DB >> 24127155

Improvement of restless legs syndrome by varenicline as antismoking treatment.

Andrea Romigi1, Giuseppe Vitrani.   

Abstract

Varenicline is a partial agonist at the α4β2 nicotinic acetylcholine receptor effective as smoking cessation pharmacotherapy. We present a familial case of severe restless legs syndrome (RLS) resistant to polytherapy who showed a consistent and effective amelioration of RLS symptoms after introduction of varenicline as antismoking drug.

Entities:  

Keywords:  Restless legs syndrome; nicotinic acetylcholine receptor agonist; varenicline

Mesh：

Substances：

Year:  2013        PMID： 24127155      PMCID： PMC3778182          DOI： 10.5664/jcsm.3092

Source DB:  PubMed          Journal:  J Clin Sleep Med        ISSN： 1550-9389            Impact factor:   4.062


  6 in total

1.  Alleviation of severe restless legs syndrome (RLS) symptoms by cigarette smoking.

Authors:  Arie Oksenberg
Journal:  J Clin Sleep Med       Date:  2010-10-15       Impact factor: 4.062

2.  Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.

Authors:  Jotham W Coe; Paige R Brooks; Michael G Vetelino; Michael C Wirtz; Eric P Arnold; Jianhua Huang; Steven B Sands; Thomas I Davis; Lorraine A Lebel; Carol B Fox; Alka Shrikhande; James H Heym; Eric Schaeffer; Hans Rollema; Yi Lu; Robert S Mansbach; Leslie K Chambers; Charles C Rovetti; David W Schulz; F David Tingley; Brian T O'Neill
Journal:  J Med Chem       Date:  2005-05-19       Impact factor: 7.446

3.  Varenicline is a potent partial agonist at α6β2* nicotinic acetylcholine receptors in rat and monkey striatum.

Authors:  Tanuja Bordia; Maya Hrachova; Matthew Chin; J Michael McIntosh; Maryka Quik
Journal:  J Pharmacol Exp Ther       Date:  2012-05-01       Impact factor: 4.030

4.  Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro.

Authors:  R Scott Obach; Anne E Reed-Hagen; Suzanne S Krueger; Beth J Obach; Thomas N O'Connell; Kathleen S Zandi; Sandra Miller; Jotham W Coe
Journal:  Drug Metab Dispos       Date:  2005-10-12       Impact factor: 3.922

5.  Cigarette smoking and the incidence of Parkinson's disease in two prospective studies.

Authors:  M A Hernán; S M Zhang; A M Rueda-deCastro; G A Colditz; F E Speizer; A Ascherio
Journal:  Ann Neurol       Date:  2001-12       Impact factor: 10.422

6.  Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute.

Authors:  Diego García-Borreguero; Richard P Allen; Ralf Kohnen; Birgit Högl; Claudia Trenkwalder; Wolfgang Oertel; Wayne A Hening; Walter Paulus; David Rye; Arthur Walters; Juliane Winkelmann; Christopher J Earley
Journal:  Sleep Med       Date:  2007-06-01       Impact factor: 3.492
  6 in total
  2 in total

Review 1.  Does Smoking Affect OSA? What about Smoking Cessation?

Authors:  Athanasia Pataka; Seraphim Kotoulas; George Kalamaras; Asterios Tzinas; Ioanna Grigoriou; Nectaria Kasnaki; Paraskevi Argyropoulou
Journal:  J Clin Med       Date:  2022-08-31       Impact factor: 4.964

2.  Open label smoking cessation with varenicline is associated with decreased glutamate levels and functional changes in anterior cingulate cortex: preliminary findings.

Authors:  Muriah D Wheelock; Meredith A Reid; Harrison To; David M White; Karen L Cropsey; Adrienne C Lahti
Journal:  Front Pharmacol       Date:  2014-07-08       Impact factor: 5.810
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.